Treatment Options for Metallo-Beta-Lactamase-Producing Enterobacterales in the Era of Increasing Resistance
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27125320 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Anastasia Golovina und 6 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine Research Center, Sirius University of Science and Technology, Olympic Ave. 1, Federal Territory "Sirius", 354340 Sochi, Russia. Hauptthemen laut MEDLINE: beta-Lactamases, Anti-Bacterial Agents, Enterobacteriaceae Infections, Enterobacteriaceae. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the grant of the state program of the "Sirius" Federal Territory "Scientific and technological development of the "Sirius" Federal T…, the state program “Scientific and technological development of the Sirius Federal Territory”.
Abstract (Originalsprache)
The escalating global burden of antimicrobial resistance constitutes a public health crisis. The World Health Organization reports that epidemiological models project 10 million deaths attributable to this issue annually by 2050. Among resistant pathogens, metallo-β-lactamase (MBL)-producing organisms represent a clinical challenge, given their consistent association with high rates of morbidity and mortality. This review summarizes effective treatment options against MBL-producing Enterobacterales. In clinical practice, a pragmatic therapeutic decision rule can be applied: when aztreonam–avibactam (ATM–AVI) is accessible and in vitro susceptibility is confirmed, it should be regarded as the preferred targeted regimen for infections caused by MBL-producing Enterobacterales. In settings where ATM–AVI is unavailable, the combination of ceftazidime–avibactam with aztreonam (CAZ–AVI + ATM) remains the treatment of choice, an approach endorsed by current recommendations from the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Critical evaluation of the published evidence is essential to inform the selection of optimal therapeutic regimens for affected patients. Novel antimicrobial agents are currently under clinical development and may broaden the therapeutic toolkit in the near future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Medicine Research Center, Sirius University of Science and Technology, Olympic Ave. 1, Federal Territory "Sirius", 354340 Sochi, Russia.
ORCID-Profile: Fedor Antipin, Olga Terina, Daniil Yakovlev, Elena Fedina, Roman Ivanov
Förderung
- This work was supported by the grant of the state program of the "Sirius" Federal Territory "Scientific and technological development of the "Sirius" Federal T…
- the state program “Scientific and technological development of the Sirius Federal Territory”
Zitieren
APA
Golovina, A., Antipin, F., Khalymbadzha, I., Terina, O., Yakovlev, D., Fedina, E., & Ivanov, R. (2026). Treatment Options for Metallo-Beta-Lactamase-Producing Enterobacterales in the Era of Increasing Resistance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27125320
Vancouver
Golovina A, Antipin F, Khalymbadzha I, Terina O, Yakovlev D, Fedina E, et al. Treatment Options for Metallo-Beta-Lactamase-Producing Enterobacterales in the Era of Increasing Resistance. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27125320
BibTeX
@article{Golovina2026,
author = {Golovina, Anastasia and Antipin, Fedor and Khalymbadzha, Igor and Terina, Olga and Yakovlev, Daniil and Fedina, Elena and Ivanov, Roman},
title = {Treatment Options for Metallo-Beta-Lactamase-Producing Enterobacterales in the Era of Increasing Resistance},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27125320}
}
EUVIMED